Registration Dossier
Registration Dossier
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 217-316-1 | CAS number: 1809-19-4
Endpoint summary
Administrative data
Description of key information
LD50 (oral, rat) > 3000 mg/kg bw
LC0 (inhalation, rat, 1h) = 22.53 mg/L
LD50 (dermal, rabbit) = 5000 mg/kg bw
Key value for chemical safety assessment
Acute toxicity: via oral route
Endpoint conclusion
- Endpoint conclusion:
- no adverse effect observed
- Dose descriptor:
- LD50
- Value:
- 3 000 mg/kg bw
- Quality of whole database:
- The key study was performed on DBHP and confirmed by the result from four other supporting studies that were performed on similar substances.
Acute toxicity: via inhalation route
Endpoint conclusion
- Endpoint conclusion:
- no adverse effect observed
- Dose descriptor:
- LC50
- Value:
- 22 530 mg/m³ air
- Quality of whole database:
- No adverse effect level up to 22.53 mg/L.
The key study was performed on DBHP and confirmed by the result from three other supporting studies that were performed on similar substances.
Acute toxicity: via dermal route
Endpoint conclusion
- Endpoint conclusion:
- no adverse effect observed
- Dose descriptor:
- LD50
- Value:
- 5 000 mg/kg bw
- Quality of whole database:
- No effect level: 4000 mg/kg. The key study was performed on DBHP and confirmed by the result from two other supporting studies that were performed on similar substances.
Additional information
There is no evidence of adverse effects of DBHP when administered to animals at dose above 2000 mg/kg bw following all routes of exposure. The oral administration shows a clinical sings at dose above 2150 mg/kg bw; for other routes of exposure there are no sings of toxicity for dosages of greater than 4000 mg/kg bw.
Justification for classification or non-classification
There is no evidence of adverse effects of DBHP when administered to animals following oral, inhalation or dermal routes of exposure, therefore, it can be assumed that:
No classification for acute oral toxicity is warranted under CLP Regulation (EC) no. 1272/2008;
No classification for acute inhalation toxicity is warranted under CLP Regulation (EC) no. 1272/2008;
No classification for acute dermal toxicity is warranted under CLP Regulation (EC) no. 1272/2008.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
